Nifty
:
17767.35
Sensex
:
60605.79
-86.70 (-0.49%)
-236.09 (-0.39%)
Nifty
Sensex
:
:
17767.35
60605.79
-86.70 (-0.49%)
-236.09 (-0.39%)

Themis Medicare Ltd.

Pharmaceuticals & Drugs - Global

Rating :
70/99

BSE: 530199 | NSE: THEMISMED

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,172.25
  • 19.27
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,224.30
  • 0.39%
  • 3.54

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 67.18%
  • 3.95%
  • 23.15%
  • FII
  • DII
  • Others
  • 0.02%
  • 0.00%
  • 5.70%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.56
  • 13.50
  • 25.09

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.99
  • 31.28
  • 21.81

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 47.89
  • 57.07

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.26
  • 14.49
  • 13.19

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.96
  • 2.44
  • 2.71

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.85
  • 19.48
  • 11.78

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Net Sales
88.78
94.92
-6.47%
91.00
107.39
-15.26%
94.44
112.50
-16.05%
79.80
61.77
29.19%
Expenses
73.51
77.63
-5.31%
69.66
83.93
-17.00%
74.08
72.03
2.85%
65.39
49.52
32.05%
EBITDA
15.27
17.29
-11.68%
21.34
23.46
-9.04%
20.36
40.47
-49.69%
14.41
12.25
17.63%
EBIDTM
17.20%
18.22%
23.45%
21.85%
21.56%
35.97%
18.06%
19.83%
Other Income
5.90
4.14
42.51%
1.97
0.21
838.10%
0.69
0.35
97.14%
1.84
0.88
109.09%
Interest
2.23
2.13
4.69%
2.37
2.05
15.61%
2.26
2.67
-15.36%
1.93
3.09
-37.54%
Depreciation
2.67
2.36
13.14%
2.56
2.38
7.56%
2.46
2.35
4.68%
2.39
2.38
0.42%
PBT
16.27
16.94
-3.96%
18.38
19.25
-4.52%
16.33
35.80
-54.39%
11.93
7.66
55.74%
Tax
4.19
4.79
-12.53%
4.85
4.13
17.43%
4.69
9.07
-48.29%
4.39
1.21
262.81%
PAT
12.08
12.15
-0.58%
13.53
15.12
-10.52%
11.63
26.73
-56.49%
7.54
6.46
16.72%
PATM
13.61%
12.80%
14.87%
14.08%
12.32%
23.76%
9.45%
10.46%
EPS
14.47
13.54
6.87%
19.33
20.95
-7.73%
18.92
33.93
-44.24%
10.82
8.76
23.52%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
354.02
394.61
230.67
201.59
183.75
209.50
216.66
232.43
201.88
195.07
173.51
Net Sales Growth
-5.99%
71.07%
14.43%
9.71%
-12.29%
-3.30%
-6.78%
15.13%
3.49%
12.43%
 
Cost Of Goods Sold
117.31
131.00
67.35
51.97
58.82
57.75
55.66
71.38
79.51
76.68
74.95
Gross Profit
236.71
263.62
163.33
149.62
124.94
151.75
160.99
161.06
122.37
118.39
98.56
GP Margin
66.86%
66.81%
70.81%
74.22%
67.99%
72.43%
74.31%
69.29%
60.62%
60.69%
56.80%
Total Expenditure
282.64
298.98
181.18
165.93
181.48
184.98
184.29
194.28
183.91
171.01
156.71
Power & Fuel Cost
-
12.18
11.32
11.49
9.70
8.41
9.77
10.83
8.36
10.04
10.03
% Of Sales
-
3.09%
4.91%
5.70%
5.28%
4.01%
4.51%
4.66%
4.14%
5.15%
5.78%
Employee Cost
-
51.97
39.99
44.28
45.69
44.65
40.00
36.30
32.64
31.14
27.27
% Of Sales
-
13.17%
17.34%
21.97%
24.87%
21.31%
18.46%
15.62%
16.17%
15.96%
15.72%
Manufacturing Exp.
-
40.23
21.41
24.01
22.45
27.46
31.30
31.28
21.69
16.38
11.80
% Of Sales
-
10.19%
9.28%
11.91%
12.22%
13.11%
14.45%
13.46%
10.74%
8.40%
6.80%
General & Admin Exp.
-
18.66
12.03
14.05
17.57
18.93
18.86
14.75
13.52
11.72
11.33
% Of Sales
-
4.73%
5.22%
6.97%
9.56%
9.04%
8.70%
6.35%
6.70%
6.01%
6.53%
Selling & Distn. Exp.
-
26.08
14.92
12.28
17.71
18.27
16.70
12.05
10.87
10.06
7.65
% Of Sales
-
6.61%
6.47%
6.09%
9.64%
8.72%
7.71%
5.18%
5.38%
5.16%
4.41%
Miscellaneous Exp.
-
18.86
14.16
7.86
9.54
9.51
11.99
17.69
17.32
14.98
7.65
% Of Sales
-
4.78%
6.14%
3.90%
5.19%
4.54%
5.53%
7.61%
8.58%
7.68%
7.88%
EBITDA
71.38
95.63
49.49
35.66
2.27
24.52
32.37
38.15
17.97
24.06
16.80
EBITDA Margin
20.16%
24.23%
21.45%
17.69%
1.24%
11.70%
14.94%
16.41%
8.90%
12.33%
9.68%
Other Income
10.40
6.54
3.62
3.46
2.67
3.49
3.32
3.19
12.59
4.90
3.34
Interest
8.79
8.77
12.71
12.88
11.82
11.87
11.84
12.33
14.53
15.63
15.28
Depreciation
10.08
9.48
8.55
8.27
7.99
7.42
7.47
11.89
11.49
9.36
8.91
PBT
62.91
83.92
31.86
17.97
-14.87
8.74
16.37
17.13
4.54
3.98
-4.05
Tax
18.12
22.38
5.63
2.09
-1.84
0.10
1.60
1.91
-0.89
1.28
2.27
Tax Rate
28.80%
26.67%
17.67%
11.63%
12.37%
1.14%
9.77%
11.15%
-19.60%
32.16%
-56.05%
PAT
44.78
61.54
26.23
15.88
-13.01
8.70
14.77
15.22
5.44
2.70
-6.32
PAT before Minority Interest
44.78
61.54
26.23
15.88
-13.03
8.64
14.77
15.22
5.44
2.70
-6.32
Minority Interest
0.00
0.00
0.00
0.00
0.02
0.06
0.00
0.00
0.00
0.00
0.00
PAT Margin
12.65%
15.60%
11.37%
7.88%
-7.08%
4.15%
6.82%
6.55%
2.69%
1.38%
-3.64%
PAT Growth
-25.93%
134.62%
65.18%
-
-
-41.10%
-2.96%
179.78%
101.48%
-
 
EPS
48.67
66.89
28.51
17.26
-14.14
9.46
16.05
16.54
5.91
2.93
-6.87

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
287.49
218.51
183.02
158.09
168.91
152.44
74.03
59.20
56.53
52.17
Share Capital
9.20
9.19
9.19
9.18
9.18
9.04
8.52
8.47
8.45
8.05
Total Reserves
278.05
208.95
173.35
148.31
159.18
141.36
65.51
50.73
48.08
43.27
Non-Current Liabilities
30.77
24.33
7.51
2.71
6.72
7.60
70.83
82.04
89.97
99.37
Secured Loans
10.91
5.73
0.09
0.14
0.01
0.47
15.89
18.83
24.47
32.08
Unsecured Loans
12.97
16.47
11.76
9.21
11.48
11.93
47.52
55.81
52.30
59.72
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.54
0.49
0.46
0.39
Current Liabilities
123.52
128.31
154.81
146.69
124.94
124.17
129.66
135.61
137.09
120.36
Trade Payables
31.87
30.79
29.68
35.04
30.55
31.63
34.90
60.15
56.97
51.65
Other Current Liabilities
29.93
39.09
46.86
43.72
29.76
38.13
37.04
16.51
23.68
14.81
Short Term Borrowings
43.10
56.93
76.61
66.86
63.73
53.45
51.88
53.78
52.74
50.55
Short Term Provisions
18.61
1.49
1.66
1.07
0.90
0.95
5.83
5.17
3.71
3.34
Total Liabilities
441.78
371.15
345.34
307.47
300.51
284.21
274.52
276.85
283.59
271.90
Net Block
144.00
133.10
116.31
123.41
125.90
123.71
117.35
122.32
121.26
123.66
Gross Block
192.36
172.24
147.14
146.06
140.78
131.17
212.16
206.19
192.01
185.14
Accumulated Depreciation
48.36
39.14
30.83
22.66
14.87
7.46
94.80
83.87
70.75
61.47
Non Current Assets
213.62
185.67
164.85
157.61
157.47
159.81
141.68
143.38
149.17
148.01
Capital Work in Progress
2.56
2.47
7.54
2.45
2.47
8.95
5.79
3.50
11.63
10.70
Non Current Investment
56.31
44.96
35.47
26.64
24.38
21.83
5.64
4.59
3.59
3.59
Long Term Loans & Adv.
6.90
2.83
2.91
2.67
2.39
3.01
12.19
12.70
12.11
9.79
Other Non Current Assets
3.84
2.31
2.62
2.45
2.33
2.30
0.70
0.28
0.58
0.27
Current Assets
228.16
185.47
180.49
149.86
143.04
124.40
132.83
133.47
134.44
123.89
Current Investments
0.00
0.00
0.00
0.00
0.00
1.05
0.00
0.00
0.00
0.00
Inventories
60.81
58.49
54.61
53.63
49.58
48.44
58.26
62.30
66.34
54.70
Sundry Debtors
100.56
77.61
102.48
72.91
68.63
48.25
47.57
45.56
39.58
32.35
Cash & Bank
26.50
24.63
5.29
3.45
6.91
8.62
14.30
8.70
6.57
12.21
Other Current Assets
40.28
5.89
5.83
5.42
17.91
18.04
12.70
16.92
21.94
24.63
Short Term Loans & Adv.
34.34
18.84
12.28
14.45
12.57
12.72
11.34
15.58
20.57
23.22
Net Current Assets
104.64
57.16
25.68
3.18
18.09
0.23
3.18
-2.14
-2.66
3.53
Total Assets
441.78
371.14
345.34
307.47
300.51
284.21
274.51
276.85
283.61
271.90

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
34.39
56.98
0.33
10.92
7.86
-1.51
25.76
19.09
8.35
4.45
PBT
95.26
41.33
26.87
-12.60
11.33
17.56
30.52
19.85
19.61
11.23
Adjustment
-0.24
7.66
9.33
16.74
14.93
15.92
10.05
10.48
8.47
7.72
Changes in Working Capital
-42.55
7.90
-35.63
7.08
-19.05
-35.16
-0.57
2.40
-2.82
3.04
Cash after chg. in Working capital
52.47
56.90
0.57
11.22
7.21
-1.67
40.00
32.73
25.26
22.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
-12.33
-14.53
0.00
0.00
Tax Paid
-18.07
0.08
-0.24
-0.30
0.65
0.16
-1.91
0.89
-1.28
-2.27
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-15.59
-15.65
-5.47
-3.72
-0.04
-4.14
-7.17
-6.27
-6.71
-4.56
Net Fixed Assets
-20.21
-20.03
-6.16
-5.34
-3.11
20.82
-6.64
-2.13
-3.68
2.13
Net Investments
-0.03
-0.02
0.06
-0.01
1.01
-1.33
0.01
-0.23
0.00
-3.09
Others
4.65
4.40
0.63
1.63
2.06
-23.63
-0.54
-3.91
-3.03
-3.60
Cash from Financing Activity
-17.55
-25.65
6.72
-9.94
-9.11
5.27
-13.29
-17.96
1.89
29.33
Net Cash Inflow / Outflow
1.26
15.68
1.59
-2.74
-1.29
-0.38
5.31
-5.14
3.52
29.23
Opening Cash & Equivalents
19.02
3.34
1.75
4.49
5.78
6.16
-39.67
-34.53
-38.05
-67.28
Closing Cash & Equivalent
20.28
19.02
3.34
1.75
4.49
5.78
-34.36
-39.67
-34.53
-38.05

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
312.22
237.41
198.67
171.54
183.39
166.38
86.94
69.91
66.90
63.75
ROA
15.14%
7.32%
4.86%
-4.29%
2.95%
5.29%
5.52%
1.94%
0.97%
-2.29%
ROE
24.35%
13.09%
9.34%
-8.00%
5.42%
13.16%
22.85%
9.40%
5.00%
-11.50%
ROCE
27.68%
15.21%
11.81%
-1.25%
8.52%
12.92%
14.69%
9.45%
9.53%
5.39%
Fixed Asset Turnover
2.16
1.44
1.38
1.28
1.56
1.32
1.13
1.03
1.04
0.94
Receivable days
82.40
142.49
158.78
140.57
100.75
77.33
72.04
76.05
66.90
83.91
Inventory Days
55.18
89.48
97.99
102.51
84.49
86.11
93.26
114.91
112.58
106.28
Payable days
87.30
163.89
75.58
71.78
69.42
73.88
99.57
126.74
123.69
137.24
Cash Conversion Cycle
50.27
68.08
181.20
171.29
115.83
89.56
65.73
64.22
55.79
52.95
Total Debt/Equity
0.27
0.39
0.54
0.52
0.48
0.55
1.73
2.37
2.61
3.02
Interest Cover
10.56
3.51
2.40
-0.26
1.74
2.38
2.39
1.31
1.25
0.74

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Themis Medicare - Quarterly Results
    3rd Feb 2023, 13:44 PM

    Read More
  • Themis Medicare launches novel transdermal Estradiol spray Lenzetto in Indian market
    4th Jan 2023, 09:35 AM

    Lenzetto is manufactured in Europe by Gedeon Richter, The Global Innovators in Women’s Health

    Read More
  • Themis Medicare gets nod to transfer API business to subsidiary
    8th Nov 2022, 10:44 AM

    Cash consideration amounting to Rs 125 crore will be payable by the transferee company to the transferor company

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.